Lung epithelium as a sentinel and effector system in pneumonia – molecular mechanisms of pathogen recognition and signal transduction by Hippenstiel, Stefan et al.
BioMed  Central
Page 1 of 17
(page number not for citation purposes)
Respiratory Research
Open Access Review
Lung epithelium as a sentinel and effector system in pneumonia – 
molecular mechanisms of pathogen recognition and signal 
transduction
Stefan Hippenstiel*, Bastian Opitz, Bernd Schmeck and Norbert Suttorp
Address: Department of Internal Medicine/Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, 13353 Berlin, 
Germany
Email: Stefan Hippenstiel* - stefan.hippenstiel@charite.de; Bastian Opitz - bastian.opitz@charite.de; 
Bernd Schmeck - bernd.schmeck@charite.de; Norbert Suttorp - norbert.suttorp@charite.de
* Corresponding author    
Abstract
Pneumonia, a common disease caused by a great diversity of infectious agents is responsible for
enormous morbidity and mortality worldwide. The bronchial and lung epithelium comprises a large
surface between host and environment and is attacked as a primary target during lung infection.
Besides acting as a mechanical barrier, recent evidence suggests that the lung epithelium functions
as an important sentinel system against pathogens. Equipped with transmembranous and cytosolic
pathogen-sensing pattern recognition receptors the epithelium detects invading pathogens. A
complex signalling results in epithelial cell activation, which essentially participates in initiation and
orchestration of the subsequent innate and adaptive immune response. In this review we
summarize recent progress in research focussing on molecular mechanisms of pathogen detection,
host cell signal transduction, and subsequent activation of lung epithelial cells by pathogens and
their virulence factors and point to open questions. The analysis of lung epithelial function in the
host response in pneumonia may pave the way to the development of innovative highly needed
therapeutics in pneumonia in addition to antibiotics.
Types of pneumonia, different types of 
pathogens, economic burden of pneumonia
Pneumonia is the third leading cause of death worldwide
and the leading cause of death due to infectious disease in
industrialized countries. In developing countries, approx-
imately 2 million deaths (20% of all deaths) of children
are due to pneumonia [1]. The majority of patients with
community-acquired pneumonia (CAP) in industrialized
countries are treated as outpatients with a low mortality
rate usually less than 1%. In patients requiring inpatient
management, the overall mortality rate increases up to
approximately 12%. Of note, lethality rate in hospitalized
patients differs significantly among different patient
groups due to comorbidity (COPD, stroke, etc.) or risk
factors (age, patients from nursing homes) [2].
In nosocomial pneumonia (hospital-acquired pneumo-
nia, HAP; health-care associated pneumonia, HCAP) mor-
tality increases substantially. HAP accounts for 15% of all
nosocomial infections, its mortality rate exceeds 30%,
although the attributable mortality is lower [3-5].
Requirement of mechanical ventilation is a high risk fac-
tor for the development of HAP with high mortality. This
form of CAP, called ventilator-associated pneumonia
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(VAP) occurs in up to 47% of all intubated patients and
varies among patient populations [6]. It definitely results
in an increased length of stay. Moreover, high mortality
rates are reported ranging from 34% in mixed medical/
surgical intensive care unit patients [7] to up to 57.1% in
heart surgical patients [8].
Consequently, CAP and HAP represent an enormous eco-
nomic burden to the public health systems. CAP alone
causes costs to the US economy of about US$ 20 billion
in the United States [9] due to more than 10 million visits
to physicians, 64 million days of restricted activity and
over 600,00 hospitalizations per year [10].
Increasing antimicrobial resistance of pathogens causing
CAP (e.g. Streptococcus pneumoniae [11,12]) and VAP (e.g.
Pseudomonas aerugenosa, Staphylococcus aureus [6,13]) as
well as the increasing number of humans with increased
susceptibility to pneumonia (e.g. geriatric and/or immu-
nocompromised people [14]) will aggravate the problem.
Consequently, the development of new preventive and
therapeutic strategies is urgently warranted.
Bacteria are the most common cause of pneumonia in
adults. Most CAP-cases are due to infections with S. pneu-
moniae, Haemophilus influenzae, and Mycoplasma pneumo-
niae  (Table 1) [15,16]. In patients with severe CAP,
Legionella  spp. as well as gram-negative bacilli and S.
aureus  have to be considered besides pneumococci
[15,16]. The majority of late onset-VAP cases is caused by
S. aureus, including antibiotic-resistant subtypes, Pseu-
domonas spp., Klebsiella spp., as well as Acitenobacter spp.
[17].
Interestingly, in children, a high rate of co-infections with
viruses such as influenza A or B as well as respiratory syn-
cytial virus (RSV) is observed in pneumococcal pneumo-
nia [18]. Tsolia et al. recently provided evidence for high
prevalence of viral infections, in particular rhinovirus
infections, in school-age children hospitalized due to CAP
[19]. Such infections have to be considered in the context
of asthma attacks in children as well as in asthma and
COPD exacerbations of adults [20-22].
Overall, in young infants, viruses such as RSV, parainflu-
enza and influenza virus are the most common cause of
pneumonia (Table 1). In immunocompromised adults, in
patients with asthma, chronic bronchitis or COPD,
viruses are more frequently identified as the causative
agent of pneumonia than in immunocompetent adult
beings [23,24]. Cytomegalovirus-related pneumonia con-
tinues to be a major cause of morbidity and mortality in
transplant recipients.
In addition to viruses, fungi like Candida spp. or Aspergil-
lus spp. induce pneumonia in the immunocompromised
host (post-transplantation, post-chemotherapy, etc.) [25].
Pneumonia due to infections with the opportunistic path-
ogen Pneumocystis jirovecii (former P. carinii) is a major
cause of illness and death in HIV/AIDS patients [26].
Table 1: Important pathogens causing pneumonia
Pathogen CAP HAP/HCAP Adults Children
Bacteria
S. pneumoniae +++ +++ +++ +++
H. influenzae ++ ++ ++ ++
M. pneumoniae +++ + ++ +++
Chlamydia spp. + (+) ++
Klebsiella spp. + ++
Legionella spp. ++ +++
S. aureus ++ +++ +++ +
P. aerugenosa ++ + + +
Acinetobacter spp. ++
Viruses
RSV ++ + +++
Rhinovirus ++ (+) ++
Influenza virus ++ + + ++
Parainfluenza virus ++ + ++
Fungi
Candida spp. ++1
Aspergillus spp. ++1
P. jirovecii +2
+ indicates the relative importance of the pathogen and the frequency of isolation in adults or children. 1 of importance in immunocompromised 
hosts. 2 important opportunistic pathogen in HIV/AIDS patients. CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, 
health-care associated pneumonia. Based on collective data [2,5,6,15-18,23,252,253].Respiratory Research 2006, 7:97 http://respiratory-research.com/content/7/1/97
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The new millennium added previously unrecognized res-
piratory viral pathogens to the list of pneumonia-causing
agents [27]. Human metapneumovirus might be the caus-
ative agent in up to 12% of young children suffering from
severe respiratory tract illness [28,29]. Avian influenza A
viruses, especially subtype H5N1, originally seen in
Southeast Asia, has caused more than one hundred cases
of severe pneumonia due to direct bird-to-human trans-
missions [30,31]. Moreover, human coronaviruses caus-
ing severe acute respiratory syndrome (SARS) as well as
two other isolates (HcoV-NL and HcoV-HKU1) were iden-
tified in the last years [30,32,33]. Thus, a number of
important emerging and reemerging pathogens have to be
added to the list of pneumonia causing agents.
The pulmonary innate immune system
A large variety of pathogens are known to cause pneumo-
nia. The innate immune system serves as the first line host
defense system against invading pathogens. Localized at
the interface between the environment and the host, the
airway epithelium does not only form a large mechanical
barrier, but it is also predisposed as a sentinel system to
detect pathogens entering via the airways and to initiate
the initial host immunological response.
Pseudostratified and columnar tracheobronchial epithe-
lium consisting of ciliated cells, secretory goblet cells and
cells with microvilli provide mechanisms for mucocilliary
clearance. In the bronchioles, cuboidal epithelium and
secretory clara cells line the airways. Alveolar type I cells
and type II cells constitute the alveolar epithelium. About
95% of the internal lung surface is built by alveolar type I
cells. Fused to endothelial cells by their basement mem-
branes both cell types together form the gas exchange bar-
rier. Alveolar type II cells fulfil many known functions,
including the regulation of the lung surfactant system
[34], alveolar fluid content [35], and are important for the
replacement of injured type I cells [34,36]. Although not
evaluated systematically, it seems predictable that differ-
entiated lung epithelial cells from different origin in the
lung will have a cell-type specific response to a given path-
ogen. This might be due to varying expression of pattern
recognition receptors (PRR), and/or cell-specific protein
expression (e.g. surfactant protein expression) [37] as well
as to different susceptibility to injury [38].
Although all pathogens causing pneumonia may directly
interact with tracheobronchial as well as alveolar epithe-
lium, the molecular mechanisms and consequences of
these interactions are poorly understood. For some of the
important pathogens mentioned, little or nothing is
known about the consequences of epithelial infection.
Taking the enormous global burden of pneumonia, the
increasing number of antibiotic- resistant bacteria, and
the emergence of new pulmonary pathogens into account,
an exact analysis of molecular mechanisms of disease is
mandatory to form a rational basis for the development of
innovative interventional procedures in pneumonia. In
this review we focus on current molecular aspects of path-
ogen-lung epithelial interactions.
Recognition of entering pathogens by lung 
epithelium
A prerequisite for the initiation of host responses is the
recognition of pathogens by the host immune system. A
tremendous progress in this field was the discovery that
the 10 germline-encoded human TLRs comprising the
TLR family act as transmembraneous pattern recognition
receptors (PRR) detecting a large variety of conserved
pathogen-associated molecular pattern (PAMP) as well as
presumably even self-molecules [39-43]. TLR activation
initiates expression of important mediators of the subse-
quent immune response. In addition, recent research
points to the existence of cytosolic PRRs, which may serve
as a second sentinel system detecting particularly but not
exclusively invasive pathogens. These include members of
the NACHT (domain present in NAIP, CIITA, HET-E, TP-
1)-LRR (leucine-rich repeats) (NLR) family [44-46], as
well as the caspase-recruitment domain (CARD)-contain-
ing RNA-helicases retinoic acid inducible gene-I (RIG-I)
and melanoma differentiation-associated gene 5 (MDA5)
Transmembraneous receptors involved in lung epithelial cell  recognition of pathogens Figure 1
Transmembraneous receptors involved in lung epithelial cell 
recognition of pathogens. Heterodimers composed of TLR2/
TLR1 or TLR2/TLR6 recognize lipoproteins and lipoteichoic 
acid. TLR4 detects LPS and bacterial factors like pneumococ-
cal pneumolysin (Ply). Flagellin, an integral structure of bacte-
rial flagella, is recognized by TLR5. Although not acting as 
classical PRRs in principle, TNF receptor-1 (TNFR1) and 
platelet activating factor receptor (PAFR) displayed an impor-
tant role in S. aureus induced pneumonia by recognition of 
staphylococci protein A or LTA, respectively. In addition, 
SARS causing coronavirus is detected by angiotensin convert-
ing enzyme 2 (ACE2) in the lung epithelium. Transmem-
braneous TLRs residing within the endosome of some cells 
detect dsRNA (TLR3), ssRNA (TLR7/8) or CpG DNA 
(TLR9).
TLR2/1
TLR2/6
TLR5 TLR4 TNFR1 PAFR ACE2
LTA
Lipopeptides Flagellin
LPS
Ply
S.a.
protein A
S.a.
LTA Coronavirus
TLR3
dsRNA
TLR7/8
ssRNA
TLR9
CpG DNA
Cytosol
EndosomeRespiratory Research 2006, 7:97 http://respiratory-research.com/content/7/1/97
Page 4 of 17
(page number not for citation purposes)
[47,48]. Both, the TLRs and the NLRs, but not the CARD-
helicases, possess LRR domains, which seem to be crucial
for pathogen recognition.
Transmembraneous receptors
In brief, TLR1, TLR2, and TLR6 are at least partly located
on the cell surface, and may collaborate to discriminate
between the molecular structures of triacyl and diacyl
lipopeptides, as well as lipoteichoic acid [49-52]. TLR4
recognizes bacterial lipopolysaccharide (LPS) [53],
whereas TLR5 detects bacterial flagellin on the cell surface
[54]. In contrast, TLR3 [55], TLR7, TLR8 [56,57] and TLR9
[58] are located in endosomal compartments and perceive
microbial nucleic acids: TLR3 recognizes viral dsRNA,
whereas TLR7 and TLR8 recognize viral single stranded
(ss)RNA. Bacterial and viral cytosine-phosphate-guanos-
ine (CpG)-containing DNA motives are recognized by
TLR9. The ligand for TLR10 has not been identified yet
[59,60] (Fig. 1).
Distribution and subcellular expression of TLRs differ
between immune cells and epithelial cells. Most results,
however, were obtained by analysis of different (immor-
talized) cell lines and a systematic exploration of TLR
receptor expression in healthy human lungs or inflamed
human lungs is still missing.
In cultured human lung epithelial cells, mRNA of all 10
TLRs has been detected [61,62]. Moreover, TLR1-5 as well
as TLR9 protein was shown to be expressed in tracheal and
bronchial epithelial cell lines [61]. Expression of TLR2,
TLR4, and TLR5 has been documented in vivo in human
airway epithelial cells [63-65] as well as TLR2 expression
in alveolar epithelial cells [66].
Besides lung epithelial cells hematopoietic cells (resident
in the lung or infiltrating during the host-pathogen com-
bat) also contribute to the host response in pneumonia.
Studies analyzing global responses in pneumonia by
using TLR-deficient mice (or C3H/Hej mice, which
express a non-functional TLR4), therefore give only lim-
ited information on the role of lung epithelial TLR expres-
sion in pneumonia. Furthermore, most studies published
focused on e.g. lethality, global bacterial burden or
immune cell recruitment. Nevertheless, studies by Wang
et al. [67] and Chu et al. [68] demonstrated important epi-
thelium-related information obtained from these models
by specific analysis of the lung epithelium. Thus, Wang et
al. showed that H. influenza induced TLR4-dependent
TNFα and MIP1α expression in lung airway epithelial
cells in vivo [67]. Moreover, by the use of TLR2-deficient
mice Chu et al. reported reduced airway mucin expression
in M. pneumoniae infected TLR2-deficient mice [68].
The expression and localization of TLRs may differ
between lung epithelial and classical immune cells. For
example, TLR4 apparently is not expressed on the surface
of the tracheobronchial epithelial cell line BEAS-2B and
the alveolar epithelial cell line A549. In these cells – which
only responded to purified TLR4 ligand LPS in much
higher doses than e.g. macrophages-TLR4 seemed to be
expressed in a intracellular compartment [69] although
contradictory results were published as well [61]. It was
suggested that under inflammatory conditions a re-locali-
sation of TLR4 to the cell membrane with subsequent
increasing susceptibility to LPS took place as documented
by studies using RSV infected lung epithelial cells [70].
Nevertheless, an increasing number of studies clearly indi-
cate that lung epithelial cells are sufficiently activated by a
broad variety of TLR ligands [39,40,71].
Lipoteichoic acid [72], commercially available peptido-
plycan [73], and M. pneumoniae [68] activated cultured
human pulmonary epithelial cells in a TLR2-dependent
manner. Results obtained with S. pneumoniae-infected epi-
thelial cells indicated a cooperative recognition of these
bacteria by TLR1 and TLR2 but not by TLR2 and TLR6
[74]. P. aeruginosa flagella as well as the C-terminus of its
cytotoxin ExoS stimulated lung epithelial cells TLR2 and
TLR5-dependently [75]. In an elegant study, Soong et al.
showed that lipid rafts-associated complexes of TLR2 and
asialoGM1 presented at the surface of airway epithelial
cells formed broadly responsive signalling complexes
reactive to important lung pathogens like P. aerugenosa or
S. aureus [76]. Notably, by using TLR2-deficient mice, the
role of TLR2 for M. pneumoniae-induced airway mucin
expression was demonstrated recently [68]. Taken
together, TLR2 represents an important functionally active
PRR on the surface of lung epithelial cells.
Double-stranded RNA, a byproduct of viral replication, is
recognized by TLR3 within the endocytoplasmic compart-
ment. Thus, TLR3 reportedly participates in the recogni-
tion of influenza A virus [77], rhinovirus [78] and detects
the synthetic viral dsRNA analog polyribocytidylic acid
[poly(I:C)] [78,79] in lung epithelial cells. Moreover, in a
model of RSV infection in TLR3-deficient mice, Rudd et al.
demonstrated that TLR3 was not required for viral clear-
ance in the lung, but it had a large impact on mucus pro-
duction [80].
TLR4 contributes to the recognition of various bacterial
pathogens by lung epithelial cells [61,69,72]. In H. influ-
enza infection, activation of the transcription factor NF-κB
and subsequent TNFα and MIP1α expression was reduced
in lung epithelial cells of TLR4-deficient mice compared
to wild-type cells, demonstrating the critical role of TLR4
in vivo for epithelial cell activation by this pathogen [67].
Consistent with this notion, two common, co-segregatingRespiratory Research 2006, 7:97 http://respiratory-research.com/content/7/1/97
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missense mutations (Asp299Gly and Thr399Ile) affecting
the extracellular domain of TLR4 reduced the response to
inhaled LPS in humans [81]. Besides LPS, other pathogen-
derived factors may also be recognized by lung epithelial
TLR4. For example, the important pneumococcal viru-
lence factor pneumolysin was found to induce a TLR4-
dependent activation of epithelial cells [74,82] and
chlamydial heat shock protein also initiated TLR4- and
TLR2-related signalling [83,84]. In addition, TLR4
together with CD14 might be involved in the recognition
of RSV fusion protein, thereby contributing to anti-viral
host defence in the lung [85]. Accordingly, TLR4 muta-
tions (Asp299Gly and Thr399IIe) may be associated with
increased risk of severe RSV bronchiolitis in human
infants, thus implicating a role of TLR4 in this virus infec-
tion [86].
Flagellin is a major structural component of flagella, a
locomotive organell present on a wide range of bacteria
[87]. It induces TLR5-dependent signalling on the surface
of host cells, which might also involve TLR4 [87]. Lung
epithelial cells were stimulated by flagella of e.g. Bordetella
bronchiseptica  [88],  P. aerugenosa [65,89], and L. pneu-
mophila [90]. The importance of this interaction was high-
lighted by the observation that a common dominant
TLR5 stop codon polymorphism leading to impaired flag-
ellin signalling is associated with increased susceptibility
to Legionaires' disease [90].
In contrast to TLR2-6, little is known about the expression
and function of TLR7-8 in lung epithelium. However,
TLR6 may function in heterodimers with TLR2 thereby
contributing to the recognition of diacylated lipoproteins
[41-43]. It is not clear if lung epithelium expresses func-
tionally active TLR7 and TLR8 although these receptors
recognize guanosine- and uridine-rich single-stranded
(ss)RNA found in many viruses.
Functionally active TLR9 was expressed in the human
alveolar tumour epithelial cell line A549 as demonstrated
by Droemann et al [66]. Although immunization of mice
with CpG motives reduced the burden of Cryptococcus neo-
formans in the lung, it is unclear if this effect was depend-
ent on lung epithelial TLR9, or more likely, induced by
TLR9-expressing immune cells causing promotion of a
sufficient Th1-type immune response [91]. However, pro-
motion of lung TLR9 signalling by using synthetic ago-
nists may enhance the host defence and may even be
beneficial in patients with acquired immune deficiency.
From an analytical perspective the use of purified viru-
lence factors has been essential for understanding PRR
function. However, infection of lung epithelial cells with
"complete" pathogens containing different PAMPs results
in a more complex, but also more realistic stimulation
(e.g. pneumococci possesses TLR2-stimulating LTA [92] as
well as TLR4-stimulating pneumolysin [74,82]). In addi-
tion, more than one TLR may be activated by one PAMP
as demonstrated for the bifunctional type-III secreted
cytotoxin ExoS from P. aerogenosa, which was shown to
activate both, TLR2 and TLR4 signalling [93].
The situation is furthermore complicated by the fact that
pathogens may modulate the expression pattern of TLRs
and induce a re-localization of the PRRs. For example,
pneumococci increased the expression of TLR1 and TLR2
in bronchial epithelial cells, but displayed no effect on
TLR4 and TLR6 expression [74]. In mice, inhalation of LPS
induced a strong increase in TLR4 protein expression in
the bronchial epithelium as well as in macrophages
within 24 hours [94]. Poly(I:C) may elevate the expres-
sion of TLR1-3 but decrease the expression of TLR5 and
TLR6 [79]. Increased expression as well as membrane
localization of TLR3 [95] and TLR4 [70] have been
observed after RSV infection of airway epithelial cells. The
effect of mixed infections with different pathogens (e.g.
influenza virus and pneumococci) on TLR expression/
localization and subsequent cell activation is widely
unknown (see below). Thus, during an infection process,
the recognition of pathogens is a dynamic process influ-
enced by varying TLR expression on pulmonary epithe-
lium. Furthermore, the liberation of cytokines (e.g. TNF-
α, IFNγ) during the initiated host response as well as ther-
apeutic interventions (e.g. corticosteroids) influences
expression of TLRs [96].
Of note, besides the traditional membranous PRRs, other
membraneous receptor molecules may also be critically
involved in epithelial activation by pathogens (Fig. 1). S.
aureus protein A binds to TNFR1 presented on airway epi-
thelial cells thereby inducing pneumonia [97]. In addi-
tion, stimulation of platelet-activating factor receptor by
S. aureus LTA, and subsequent epidermal growth factor
receptor activation may stimulate mucus expression and
cell activation in lung epithelium independently of TLR2
and TLR4 [98]. Angiotensin converting enzyme 2 (ACE2)
expressed in the lung has recently been identified as a
potential SARS coronavirus receptor and SARS and the
Spike protein of this virus reduced the expression of ACE2
[99,100]. Notably, blocking of the renin-angiotensin
pathway reduced the worsening of disease induced by
injection of Spike protein in mice [100]. Thus, non-classi-
cal pathogen-recognizing transmembranous receptors
may also be important for the pathophysiology of pneu-
monia.
Cytosolic receptors
Various bacterial lung pathogens like C. pneumoniae
[101,102], L. pneumophila [103,104], and S. pneumonia
[105,106] are able to invade and replicate efficientlyRespiratory Research 2006, 7:97 http://respiratory-research.com/content/7/1/97
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within epithelial cells. Inside the cells, these pathogens are
protected against detection and attack by various defense
mechanisms of the innate immune system. Not only
whole bacteria are sensed intracellularly, the same is true
for bacterial proteins or genetic material after injection
into host cells via various bacterial secretion systems (e.g.
type III or IV secretion system) [107-110]. Moreover,
many viruses replicate very efficiently within the lung epi-
thelium. Recent research provided evidence that cytosolic
PRRs exist which detect these invasive pathogens and ini-
tiate an appropriate immune response [44-46] (Fig. 2).
The human NLR family, currently consisting of 22 pro-
teins, contains NALP (NACHT-, LRR-, and pyrin domain-
containing proteins), NOD (nucleotide-binding oli-
gomerization domain), CIITA (class II transactivator),
IPAF (ICE-protease activating factor) and NAIP (neuronal
apoptosis inhibitor protein). These proteins are impli-
cated in the detection of intracellular pathogens or other
general danger signals [44-46]. Two of the best character-
ized members of the NLRs are NOD1 and NOD2
[44,45,111]. In general, the importance of NOD proteins
has been highlighted by the findings that critical muta-
tions are associated with inflammatory granulomatous
disorders (e.g. Chrohn's disease, Blau syndrome) [112]. In
addition, an insertion-deletion polymorphism of the
NOD1 gene effecting the LRR domain has been associated
with asthma and high IgE levels as suggested recently
[113,114].
NOD proteins share a tripartite domain structure: The car-
boxy-terminal LRR domain seems to mediate ligand rec-
ognition (Fig. 2). The central NOD (NACHT) domain
exhibits ATPase activity and facilitates self-oligomeriza-
tion. An amino-terminal localized caspase-recruitment
domain (CARD) (one CARD domain in NOD1, two in
NOD2) mediates protein-protein interaction [44-46].
NOD1 is activated by peptidoglycan-derived peptides
containing  γ-D-glutamyl-meso-diaminopimelic acid
found mainly in Gram-negative bacteria [115,116],
whereas NOD2 mediates responsiveness to the muramy-
dipeptide MurNAc-L-Ala-D-isoGln conserved in pepti-
doglycans of basically all bacteria [117,118]. However, as
for many of the TLRs and their agonists, there is no formal
proof for the binding of the peptidoglycan motifs to the
LRR domains of NOD1 and NOD2.
So far it is unclear how cytoplasmic NODs find their lig-
ands: Some bacteria such as Shigella and Listeria reach the
free cytosol of host cells [119]. Furthermore, injection of
peptidoglycan-derived molecules in the host cell cytosol
by type IVb secretion system-expressing bacteria (e.g. L.
pneumophila [109]) has also to be considered since this
mechanism was evidenced in experiments with Helico-
bacter pylori [110]. In addition, the peptide transporter
PEPT1 was suggested to play a role in the uptake of
muramyldipeptide and subsequent proinflammatory
intestinal epithelial cell activation [120]. Thus, it is rea-
sonable to speculate that the high-affinity peptide trans-
porter PEPT2 expressed in the respiratory tract epithelium
[121] is involved in NOD-peptidoglycan-related lung cell
activation.
Although residing in the cytosol, it was shown that in
intestinal epithelium, membrane recruitment of NOD2
was essential for NF-κB activation by muramyl dipeptide
[122]. As known so far, NOD1 is ubiquitously expressed
whereas NOD2 is primarily found in antigen presenting
cells and epithelial cells. In human lung epithelium, we
detected expression of NOD1 and lower expression of
NOD2 in resting human BEAS-2B cells [106]. Further
analysis revealed that intracellular pneumococci were rec-
ognized by NOD2 but not by NOD1 in epithelial cells.
Moreover, NOD1 was implicated in lung infections with
P. aerugenosa [123], and NOD2 in Mycobacterium tubercu-
losis infection [124]. In addition, our unpublished experi-
ments indicated an important role of NOD1 in lung
epithelial cell activation by L. pneumophila. Moreover, the
respiratory pathogen C. pneumoniae activated human
endothelial cells via NOD1 suggesting a role of this mole-
Recognition of pathogens by cytosolic PRRs Figure 2
Recognition of pathogens by cytosolic PRRs. (A) As an exam-
ple, NOD1 is shown. NOD1 is activated by peptidoglycan-
derived peptides. The carboxy-terminal LRR domain is 
involved in agonist recognition, whereas the central NOD 
(NACHT) domain has ATPase activity and facilitates self-oli-
gomerization. At the amino-terminal a protein-protein inter-
action mediating caspase-recruitment domain (CARD) is 
localized (one CARD domain in NOD1, two in NOD2). 
Recruitment of the kinase-activity containing adaptor mole-
cule RICK transmits the signal to the NF-κB pathway and it 
may also participate in MAPK stimulation. (B) The cytosolic 
PRRs MDA5 and RIG-I recognize dsRNA leading to a com-
plex signalling pathway involving molecules like IPS-1, Rip, 
FADD promoting NF-κB activation, whereas IPS, TBK and 
IKKi mediate IRF3 activation.
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cule also in lung infection [125]. The observation that
NOD1 was involved in infection with H. pylori [110] and
Listeria monocytogenes [126] further strengthened the
hypothesis that NOD proteins act as important cytosolic
PRRs.
After infection of pulmonary epithelial cells with S. pneu-
moniae, expression of NOD1 and NOD2 increased in
these cells in vitro and overall expression was up-regulated
in mouse lungs infected with pneumococci [106]. IFNγ,
has been shown to increase NOD1 expression in epithe-
lial cells [127], and TNFα as well as IFNγ, up-regulated
expression of NOD2 [128]. Thus, as already explained for
TLRs, the expression of cytosolic PRRs may also vary dur-
ing the hassle with pathogens and the subsequent activa-
tion of the host immune system.
Besides NOD1 and NOD2, additional members of the
NLR family may have a role in pneumonia. For example,
L. pneumophila replicates in macrophages derived from A/
J mice, but not in cells derived form other mouse-inbred
strains. The higher susceptibility of A/J mice towards
Legionella infection has been attributed to sequence differ-
ences and reduced expression of the NLR protein Naip5
(Birc1e) [129,130]. Accordingly, recent studies demon-
strated that Naip5 together with IPAF or ASC recognizes
Legionella flagellin and controls intracellular replication of
Legionella within mice macrophages, and mediates IL-1β
secretion, respectively [131-133]. Thus, at least in mice,
bacterial flagellin is recognized by both, TLR5 on the cell
surface and Naip5 within the cytosol.
As a great number of other members of the NLR protein
family, such as NALP proteins (with exception of
NALP10) also contain LRR domains implicated in patho-
gen recognition, additional members of this family may
function as cytosolic PRRs or may be involved in inflam-
matory signalling [44,45,134,135]. For example, Nalp3/
cryoporin has recently been demonstrated to mediate IL-
1β and IL-18 secretion induced by a diverse variety of
stimuli such as bacterial or viral RNA, muramyl dipeptide,
TLR agonists, together with ATP, native bacteria (e.g. S.
aureus) and bacterial toxins [136-139].
An important question is how activation of transmembra-
nous and cytosolic receptors acts together in host cell
responses. For example, a synergistic stimulation of
cytokine induction by NOD1 or NOD2, together with
TLRs has been observed in human dendritic and mono-
cytic cells [140-143], while NLR proteins may act as inhib-
itors of TLR signalling. Overexpression of the NALP12 for
example was shown to reduce TLR2/4- and M. tuberculosis-
related activation of myeloid/monocytic cells [144].
Moreover, in vivo studies in NOD2-deficient mice or mice
carrying a common Crohn's disease-associated NOD2
mutation yielded controversial results regarding func-
tional NOD2/TLR2 interaction [145-147].
dsRNA is produced as an intermediate product during
virus replication and recent observations point to the
existence of cytosolic PRRs recognizing viral dsRNA (Fig.
2). Both, RIG-I and MDA5 recognizes dsRNA leading to
activation of an antiviral response [47,48]. RIG-I and
MDA5 comprise a carboxy-terminal DexD/H-box RNA
helicase domain which seems to mediate recognition of
dsRNA, whereas amino-terminal CARD domains mediate
the recruitment of downstream signalling adaptor mole-
cules [47,48]. Matikainen et al. reported that IFNβ and
TNFα induced the expression of RIG-I in A549 cells.
Expression of dominant-negative form of RIG-I inhibited
influenza A virus-related activation of an IFNβ promoter
suggesting a role of lung epithelial RIG-I in host defense
[148]. Very recent studies in mice deficient in RIG-I or
MDA5 indicated that RIG-I mediated IFN response to
RNA viruses including influenza virus and MDA5 recog-
nized picornavirus-infection [149]. Increased susceptibil-
ity of RIG-I-deficient mice towards influenza virus
infection highlights the importance of this molecule for
lung infection [149].
Besides these studies, however, nothing more is currently
known about the expression of these molecules and their
functional role in lung epithelial inflammation and dis-
ease.
Downstream signalling pathways
The recognition of PAMPs by PRRs activates a network of
signal transduction pathways. Although it is reasonable to
suggest that most of these pathways function in pulmo-
nary epithelial cells and in classical immune cells simi-
larly in principle, most data have not been verified in
human lung epithelial cells or in the lung in vivo. In the
following, a brief introduction in basic mechanisms is
given with special emphasis on signalling pathways
known to be operative in lung epithelium.
In general, a central aspect of inflammatory activation by
PRRs is the stimulation of NF-κB-dependent gene tran-
scription [40,44,59,60]. On the other hand, increasing
evidence points to an important role of interferon-regulat-
ing factor (IRF)-dependent gene transcription leading to
the generation of type I interferons (IFN) and subsequent
expression of co-called IFN-stimulated genes (ISGs) [150-
152].
The ability of the TLRs to activate transcription factors
leading to gene transcription differs and depends on dif-
ferential engagement of the four TIR (Toll-interleukin-1
receptor) domain containing adaptor molecules MyD88
(differentiation primary response gene 88), TIRAP (toll-Respiratory Research 2006, 7:97 http://respiratory-research.com/content/7/1/97
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IL-1R domain-containing adaptor protein; Mal), TRIF
(Toll/IL-1R domain-containing adaptor inducing IFNβ)
and TRAM (Fig. 3). Thus, whereas all TLRs except TLR3
engage MyD88 in order to activate NF-κB and AP-1
[153,154], only TLR3 and TLR4 signal via TRIF and TRIF/
TRAM, respectively, leading to additional activation of
IRF3 and potentially IRF7 [155-158]. The forth adaptor
TIRAP is recruited to TLR2 as well as TLR4 and is involved
in the MyD88-dependent transcriptional activation of NF-
κB [159,160]. In case of the conserved MyD88-dependent
signalling leading to NF-κB activation, further signalling
molecules, such as IRAK4 (interleukin-1 receptor-associ-
ated kinase-4), IRAK1, as well as TRAF6 (tumor necrosis
factor receptor-associated factor-6), are additionally
recruited downstream of MyD88 to the receptor complex
[43,59]. Downstream of TLR7-9, a similar signalling mod-
ule leads to the activation of IRF5 and IRF7 [161-165].
Small GTP binding Rho proteins like Rac1 may also par-
ticipate in TLR-driven NF-κB dependent gene transcrip-
tion, as recently shown for pneumococci infected human
lung epithelial cells [74]. The canonical NF-κB pathway
downstream the TLRs involves phosphorylation of IκB
molecules sequestering NF-κB in the cytosol in unstimu-
lated cells by the IKK (IκB kinase) complex finally leading
to the proteosomal-mediated degradation of IκB
[59,166]. Free NF-κB molecules translocate into the
nucleus and initiate NF-κB dependent gene transcription
[59,166].
Stimulation of this NF-κB activation was observed e.g.
after infection of lung epithelial cells with pneumococci
[74,167], Moraxella catharrhalis [168], P. carinii [169], P.
aerogenosa [170], or exposure to purified virulence factors
like LPS [171]. In addition to stimulation of transmem-
braneous TLRs, activation of NOD1 and NOD2 also
results in NF-κB activation. Both NODs recruit the adap-
tor molecule RICK/Rip2 through CARD-CARD interac-
tion [172,173] and we recently implicated the
downstream signalling molecules IRAK1, IRAK2, TRAF6
as well as NIK (NF-κB-inducing kinase), TAB2 (transform-
ing growth factor-β activated kinase binding protein) and
TAK1 (transforming growth factor-β activated kinase) in
S. pneumoniae initiated NOD2-dependent NF-κB activa-
tion in epithelial cells [106].
The important role of NF-κB activation for lung inflam-
mation was furthermore emphasised by Sadikot et al.,
who demonstrated that selective overexpression of consti-
tutively active IκB kinase in airway epithelial cells by ade-
noviral vectors was sufficient to induce NF-κB activation,
inflammatory mediator production and neutrophilic lung
inflammation in mice [174]. Moreover, by using the same
experimental approaches, this group showed most
recently that inflammatory signalling through NF-κB in
lung epithelium is critical for proper innate immune
response to P. aeruginosa [175]. In addition, inhibition of
NF-κB by airway epithelium selective overexpression of an
IκB suppressor reduced the inflammatory response upon
intranasal application of LPS [171]. Overall, NF-κB activa-
tion is a central event in pathogen exposed lung epithe-
lium.
As mentioned above, a key feature of some but not all
TLRs is the initiation of IRF-dependent gene transcription.
The cytosolic PRRs RIG-I and MDA5 are also capable to
induce IRF3 and IRF7 activation [47,48] (Fig. 2). How-
ever, in contrast to the well-established canonical NF-κB
pathway, the mechanisms of IRF activation are much
more elusive and require further investigation. The com-
plexity of these pathways may be illustrated by exempla-
rily focussing on IRF3, which is crucial for e.g. initial IFNβ
expression. Different molecules like IFNβ promoter stim-
ulator 1 (IPS-1, also known as MAVS, VISA, Cardif) (Fig.
2), TBK1, IKKi, or PI3 kinase pathway are implicated in
the IRF3 activation process [176-182]. Activation of IRFs
is vital for the regulation of type I (IFNα-subtyps, IFNβ, -
ε, -κ, -ω) expression, participating in the host response
against viruses and, notably, intracellular bacteria
[183,184]. Besides acting on classical immune cells,
TLRs mediate activation of NF-κB- and IRF-related gene  transcription Figure 3
TLRs mediate activation of NF-κB- and IRF-related gene 
transcription. (A) Examples of recruited adaptor molecules 
critical for TLR4 function. With the possible exception of 
TLR3, all TLRs share a MyD88-dependent pathway for the 
activation of NF-κB. A protein complex composed of TIRAP, 
MyD88, IRAK4, IRAK1 and TRAF6 mediates NF-κB stimula-
tion. In addition, TRAM, TRIF as well as TRAF6 and TBK1 
stimulate IRF3 activation. (B) Located in the endosomal 
membrane, TLR3 recognizes dsRNA. Whereas TRIF recruit-
ment connects TLR3 via TBK1 to IRF3 activation, further 
recruitment of RIP1 and TRAF6 stimulates NF-κB.
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expression of type I IFNs resulted in auto- and paracine
stimulation of cells through specific receptors (IFNAR),
stimulation of janus kinases, STATs, and subsequent
expression of ISGs in epithelial cells [183,184]. Thus,
although intracellular bacteria and viruses are important
lung pathogens, neither the expression of central signal-
ling molecules nor the resulting signalling events are
known to date in lung epithelial cells.
Another important signalling pathway involves mitogen-
activated protein kinases (MAPK). Pro-inflammatory sig-
nalling induced by several TLRs [59,185] as well as NOD1
and NOD2 involves the activation of ERK (extracellular
signal-regulated kinase), JNK (c-Jun N-terminal kinase),
and p38 MAPK [126,145,186]. Activation of these kinases
was also observed e.g. in pneumococci- [74,167] or virus-
infected [187] lung epithelium and in pneumococci-
infected mice lungs [167].
The finding that e.g. the p38 MAPK pathway converges
with the NF-κB pathway in IL-8 regulation illustrates the
complex signalling network in infected lung epithelial
cells: Blockade of p38 MAPK activity did not affect pneu-
mococci-induced nuclear translocation and recruitment
of NF-κB/RelA to the il8 promoter but reduced the level of
phosphorylated RelA (serine 536) at the il8  promoter
[167]. The inhibition of serine 536-RelA phosphorylation
blocked pneumococci-mediated recruitment of RNA
polymerase II (Pol II) to il8 promoter thereby averting IL-
8 expression [167] (Fig. 4). Thus, p38 MAP kinase contrib-
utes to pneumococci-induced chemokine transcription by
modulating p65 NF-κB-mediated transactivation in
human lung epithelial cells.
DNA in euchromatin must be processed to allow for
access of activated transcription factors. Increasing evi-
dence indicates that histone modifications may serve as
combinatorial code for the transcriptional activity state of
genes in many cellular processes by loosening the DNA-
histone interaction and unmasking of transcription factor
binding sites [188]. In chromatin, 146 base pairs of DNA
are wrapped in 1.65 turns around a histone octamer
(H2A, H2B, H3, H4)2 [189]. A wide range of specific cov-
alent modifications of accessible N-terminal histone tails
are decisive for transcription repression or gene activation
[190]. To date, acetylation (mostly lysine), phosphoryla-
tion (serine/threonine), methylation (lysine), ADP-ribo-
sylation, and ubiquitination of histones have been
described [191,192]. Phosphorylation at Ser-10 on H3
and acetylation at Lys-14 of H4 seem to have a special
impact on gene regulation [189]. For example, it was
found that LPS stimulation of dendritic cells induced p38
MAPK-dependent phosphorylation at Ser-10 on H3 and
acetylation at Lys-14 on H4 specifically occurs at il8, and
mcp1, but not at tnfα or mip1α genes [193]. Both modifi-
cations have been correlated with the immediate early
gene induction. In addition, L. monocytogenes-related
recruitment of histone acetylase (HAT), CBP and Pol II to
the il8 promotor and subsequent il8 gene expression in
human endothelial cells depended on p38 MAPK-related
acetylation (Lys-8) of histone H4 and phosphorylation/
acetylation (Ser-10/Lys-14) of histone H3 at the il8 pro-
moter [194]. Furthermore, we recently demonstrated that
M. catharrhalis enhanced global acetylation of histone H3
and H4 and at the il8 gene in human bronchial epithelial
cells [168]. For this infection, global histone deacetylase
(HDAC) expression as well as its activity decreased [168].
Considering that patients with chronic obstructive pul-
monary disease (COPD) which are often colonized by
Moraxella also display decreased HDAC activity [195,196],
acute and chronic effects of histone-related (epigenetic)
modifications should be taken into account in lung infec-
tion.
Besides the signaling pathways mentioned, other path-
ways, including e.g. tyrosine kinases [197] or protein
kinase C [198], may also play an important role, but have
not been analyzed yet in detail in pulmonary epithelium.
Importantly, most investigations focused on the effects
purified virulence factors (e.g. LPS) or – at the most – of
one pathogen. This approach does not take into account
that mixed or sequential infections with different patho-
gens (e.g. influenza virus and pneumococci) causing
severe pneumonia may occur. In a sequential infection
model RSV infection lead to impaired clearance of S. pneu-
moniae,  S. aureus or  P. aerugenosa [199]. In addition,
reduced clearance of pneumococci was observed after
influenza A virus infection [200]. Polymicrobial coloniza-
tion of lung epithelial cells by pneumococci and H. influ-
enzae led to strong NF-κB activation and synergistic IL-8
expression and synergistic inflammation in mice in vivo
[202]. Virus infection in concert with endogenous pro-
inflammatory mediators may alter PRR expression in lung
epithelium as evidenced for TLR3 [201] and RIG-I [148].
Thus, co-infections or mixed infections certainly will
influence pathogen recognition, signal transduction and
host gene transcription thereby opening up an important
new field of research.
In conclusion, a complex network of signalling events is
started through the recognition of pathogens by lung epi-
thelial cells.
Consequences for lung epithelial cell activation
The complex response of the lung epithelium to pathogen
recognition reflects the great variety of stimuli and signal-
ling pathways activated. The epithelial response includes
production and secretion of inflammatory mediators such
as cytokines and chemokines, the up-regulation of epithe-Respiratory Research 2006, 7:97 http://respiratory-research.com/content/7/1/97
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lial cell surface adhesion molecules as well as the
enhanced liberation of antimicrobial peptides
[39,40,71,203,204].
For example, a broad variety of purified virulence factors
(e.g. flagella [75], LPS [72], LTA [72]) as well as complete
bacteria (e.g. S. pneumoniae [74,106,167], P. aerugenosa
[62,76], S. aureus [62], M. catharrhalis [168]) induced the
liberation of the chemotactic cytokine IL-8, which is con-
sidered to play an important role in lung inflammation
[205]. Agonists of e.g. TLR2, TLR4 and TLR9 stimulated
the expression of TNFα as well as IL-6 by lung epithelium
[61,70,96].
In addition, the pathogen-related liberation of cytokines
by epithelial cells results in auto- and paracrine stimula-
tion of further inflammation-regulating mediators. Sys-
tematic analysis of TNFα and IL-1β exposed primary
human bronchial epithelial cells by cDNA representa-
tional difference analysis discovered over 60 regulated
genes including proteases and antiproteases, adhesion
molecules, as well as cyto- and chemokines [206].
Up-regulation of adhesion molecules like intercellular
adhesion molecule 1 (ICAM-1) or vascular cell adhesion
molecule-1 (VCAM-1) in pulmonary epithelium was
observed after exposure to diverse stimuli such as LPS
[40,61,207], outer membrane protein A from K. pneumo-
niae [208] or infection with P. carinii [209]. The liberation
of immunodulatory cyto- and chemokines and up-regula-
tion of adhesion molecules mediates the acute immune
response by e.g. recruitment of leucocytes to the site of
infection and modulates the initiation of adaptive
immune response. In addition, systemic effects of lung
epithelial inflammation by the release of e.g. granulocyte-
macrophage colony-stimulating factor (GM-CSF) by acti-
vation of immature precursor cells have to be considered
[210]. GM-CSF secretion was shown in S. pneumoniae-
infected bronchial epithelial cells as well as in pneumo-
cocci-infected mice lungs [167].
Antimicrobial substances like defensins and cathelicidins
secreted by pulmonary epithelium [203] are capable of
killing Gram-positive and -negative bacteria, some fungi
as well as enveloped viruses [211-213]. Some of these fac-
tors, like human β-defensin (hBD)-2 have shown to be
up-regulated by cytokines as well as by bacteria like P.
aerogenosa in lung epithelial cells [214].
In addition, inflamed epithelium may show increased ara-
chidonic acid metabolism. In pneumococci-infected lung
epithelium as well as in pneumococci-infected mice lung
increased cyclooxygenase-2 expression and subsequently
increased prostaglandin E2 (PGE2) liberation was noted
[215]. PGE2 in turn may influence immune cells, blood
perfusion distribution as well as lung function [216].
The epithelium thereby closely interacts with other cellu-
lar components of the innate immune system such as
phagocytes (neutrophils, macrophages), natural killer
cells and others [217-221]. Of note, today the exact con-
tribution of parenchymal lung versus hematopoietic cells
to the initiation and control of the immune response
within the lung is not entirely clear and seems to be path-
ogen-specific as evidenced by studies using chimeric
mouse models. In P. aerugenosa-infected mice lungs,
expression of MyD88 in non-bone marrow derived cells is
required for the early control of infection, including
cytokine production and neutrophil recruitment, whereas
on the long run both, parenchymal and hematopoietic
cells were required to control pathogen replication [222].
After inhalation of endotoxin, the cytokine response
seems to be mediated by hematopoietic cells in a myeloid
differentiation primary response gene (88) (MyD88)-
dependent way, whereas bronchoconstriction depended
on resident cells as indicated by experiments with chi-
meric mice [223]. In studies using TLR4-deficient chi-
meric mice, expression of TLR4 on hematopoietic cells
Histone modifications regulate the accessibility of the DNA  to transcription factors Figure 4
Histone modifications regulate the accessibility of the DNA 
to transcription factors. (A) In most cases, hyperacetylation 
(Ac) of histones loosens DNA-histone interaction thereby 
making gene promoters amenable for the binding of tran-
scription factors. After stimulation of transmembraneous 
(e.g. TLRs) or cytosolic (e.g. NODs) PRRs histone acetylases 
(HATs) may be recruited whereas histone deacetylases 
(HDACs) may disappear resulting in increased histone 
acetylation. (B) In addition, after binding of the transcription 
factors to the DNA further modification of the bound tran-
scription factor by PRR-mediated MAPK-dependent phos-
phorylation may be necessary to induce recruitment of the 
basal transcription apparatus of the cell and subsequent gene 
transcription as shown for pneumococci infected pulmonary 
epithelial cells.
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and macrophages seemed crucial to initiate the LPS-
induced recruitment of neutrophils within the alveolar
space [224]. On the other hand, inhibition of the nuclear
factor-κB (NF-κB) pathway in distal lung epithelium lead
to reduced neutrophilic lung inflammation and cytokine
expression [171,225].
In addition, the interaction of lung epithelium with
hematopoietic cells may alter the immune response of
both cell types. Transmigration across lung epithelial cells
decreased apoptosis of polymorphonuclear leucocytes
[226,227] and migration over the surface of alveolar epi-
thelial cells facilitated alveolar macrophage phagocytic
activity in a ICAM-1-dependent manner [228]. On the
other hand, LPS-exposed mononuclear phagocytes
induced the expression of human β-defensin-2 in lung
epithelial cells, thereby strengthening the epithelial innate
immune response [229]. Moreover, the complex interac-
tion is further highlighted by the observation that
defensins produced by neutrophils may stimulate the
release of cytokines by epithelial cells and promote epi-
thelial cell proliferation [230-232].
Overall, it is reasonable to suggest that the pulmonary epi-
thelium contributes significantly to the initiation of an
appropriate immune response in pneumonia. Further-
more, the transition of the innate to adaptive immune
response might significantly be modulated by epithelial-
related actions. Finally, although poorly examined and
not discussed here, the lung epithelium may also possess
mechanisms to negatively control and terminate inflam-
matory responses [233].
Concluding remarks
Pulmonary epithelium is well equipped to act as an inter-
active sentinel system detecting entering pathogens. Rec-
ognition of pathogens or their products by
transmembraneous and intracellular receptors activated
signalling cascades leading to a complex activation status
of pulmonary epithelium and influences local and sys-
temic immune response. Although pneumonia is a com-
mon worldwide disease, causing millions of deaths
annually, central mechanisms of pathogen-lung epithelial
interaction are still obscure. Basic questions, like the
expression of functional active transmembraneous and
cytosolic PRRs in normal and inflamed human lungs, are
widely unanswered. Results about PRR function are often
obtained in classical immune cells and transferred to pul-
monary lung epithelial cells function although important
differences may exist (e.g. TLR4 expression and localiza-
tion). For many important lung pathogens only fragmen-
tary information about their interaction is available. In
addition, the modulatory role of alveolar fluid containing
immunregulatory surfactant proteins needs further inves-
tigation [234-237]. Finally, the complexity, which is intro-
duced by co-infections and subsequent infection must be
appreciated in further studies.
Overall, it seems imperative to accelerate the verification
of important general mechanisms of innate immunity for
the organ lung with respect to pneumonia. In addition,
the lung is a unique organ and it is important to identify
organ specific mechanisms of innate immunity. The rela-
tive ease of transnasal or tracheal application of small
interference RNA might allow a relatively fast verification
of important newly identified molecules in vivo without
the time-consuming establishment of knock out models
[238-240].
In addition to the analysis of host response initiation, the
understanding of control mechanisms of local inflamma-
tion within the lung (resolution of inflammation, repair
mechanisms) is crucial [241-243]. In the lung, a high
degree of organ function must be preserved on a minute
basis to allow for sufficient gas exchange. In this sense,
lungs differ from gut or kidney, because inflammation in
the lungs must be controlled much more tightly. Of note,
as noticed for the intestinal epithelium [244,245], lung
epithelial PAMP recognition may be somewhat restricted
to avoid frequent epithelial-mediated inflammation.
Ambient air contains bacteria and endotoxin [246], and
the aerosolized concentrations of e.g. endotoxin is
increased in e.g. agricultural environments [247,248].
Limitation of pro-inflammatory lung epithelial activation
may be due to restriction of PRR expression on epithelial
surfaces [69,70], reduced expression of co-signalling mol-
ecules (as shown for e.g. MD-2 [249]), or increased
expression of inhibitory molecules (e.g. TOLLIP
[250,251]).
Overall, there are a lot of important questions about the
molecular mechanisms by which the lung epithelium acts
in pneumonia. Their analysis may help to develop future
innovative therapeutic strategies in pneumonia.
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